

Chapter 9

REFERENCES

1. Grayburn PA, Hillis LD. Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. *Ann Intern Med.* 2003;138(6):506-511.
2. Goldman L. The revised cardiac risk index delivers what it promised. *Ann Intern Med.* 2010;152(1):57-58.
3. Kikura M, Oikawa F, Yamamoto K, et al. Myocardial infarction and cerebrovascular accident following non-cardiac surgery: differences in postoperative temporal distribution and risk factors. *J Thromb Haemost.* 2008;6(5):742-748.
4. Bennett-Guerrero E, Welsby I, Dunn TJ, et al. The use of a postoperative morbidity survey to evaluate patients with prolonged hospitalization after routine, moderate-risk, elective surgery. *Anesth Analg.* 1999;89(2):514-519.
5. Fleischmann KE, Goldman L, Young B, Lee TH. Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay. *Am J Med.* 2003;115(7):515-520.
6. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. *CMAJ.* 2005;173(6):627-634.
7. Bartels C, Bechtel JF, Hossmann V, Horsch S. Cardiac risk stratification for high-risk vascular surgery. *Circulation.* 1997;95(11):2473-2475.
8. Garcia S, Moritz TE, Goldman S, et al. Perioperative complications after vascular surgery are predicted by the revised cardiac risk index but are not reduced in high-risk subsets with preoperative revascularization. *Circulation.* 2009;2(2):73-77.
9. McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. *Eur Heart J.* 2008;29(3):394-401.
10. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation.* 1999;100(10):1043-1049.
11. Ashton CM, Petersen NJ, Wray NP, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. *Ann Intern Med.* 1993;118(7):504-510.
12. Lie SA, Pratt N, Ryan P, et al. Duration of the increase in early postoperative mortality after elective hip and knee replacement. *J Bone Joint Surg Am.* 2010;92(1):58-63.
13. Lopez-Jimenez F, Goldman L, Sacks DB, et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. *J Am Coll Cardiol.* 1997;29(6):1241-1245.
14. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. *Anesthesiology.* 1998;88(1):7-17.
15. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA.* 2004;291(17):2092-2099.
16. Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. *Anesthesiology.* 2005;102(5):885-891.
17. Foster ED, Davis KB, Carpenter JA, Abele S, Fray D. Risk of noncardiac operation in patients with defined coronary disease: The Coronary Artery Surgery Study (CASS) registry experience. *Ann Thorac Surg.* 1986;41(1):42-50.
18. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation.* 1997;95(8):2037-2043.
19. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. *Circulation.* 2001;103(7):934-940.
20. Fujii K, Kobayashi Y, Mintz GS, et al. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. *Circulation.* 2003;108(20):2473-2478.
21. Thygesen K, Alpert JS, White HD, Joint ESCA/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J.* 2007;28(20):2525-2538.
22. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. *Circulation.* 2009;119(22):2936-2944.
23. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. *Int J Cardiol.* 1996;57(1):37-44.
24. Ellis SG, Hertzner NR, Young JR, Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. *Am J Cardiol.* 1996;77(12):1126-1128.

25. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. *Cardiovasc Pathol.* 1999;8(3):133-139.
26. Matyal R. Newly appreciated pathophysiology of ischemic heart disease in women mandates changes in perioperative management: a core review. *Anesth Analg.* 2008;107(1):37-50.
27. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med.* 2004;351(27):2795-2804.
28. Boden WE, O'Rourke RA, Teo KK, et al. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE trial). *Am J Cardiol.* 2009;104(1):1-4.
29. Teo KK, Sedlis SP, Boden WE, et al. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. *J Am Coll Cardiol.* 2009;54(14):1303-1308.
30. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. *Anesth Analg.* 2005;100(6):1576-1583.
31. Donahue BS. Factor V Leiden and perioperative risk. *Anesth Analg.* 2004;98(6):1623-1634.
32. Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. *Histopathology.* 2007;50(5):535-546.
33. Biasucci LM, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. *Circulation.* 2004;110(25):e560-567.
34. Breslow MJ, Jordan DA, Christopherson R, et al. Epidural morphine decreases postoperative hypertension by attenuating sympathetic nervous system hyperactivity. *JAMA.* 1989;261(24):3577-3581.
35. Liu SS, Wu CL. Effect of postoperative analgesia on major postoperative complications: a systematic update of the evidence. *Anesth Analg.* 2007;104(3):689-702.
36. Wallace AW. Clonidine and modification of perioperative outcome. *Curr Opin Anaesthesiol.* 2006;19(4):411-417.
37. Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. *Anesth Analg.* 1999;88(3):477-482.
38. Walsh SR, Tang T, Sadat U, Dutka DP, Gaunt ME. Cardioprotection by remote ischaemic preconditioning. *Br J Anaesth.* 2007;99(5):611-616.
39. Jones WK, Fan G-C, Liao S, et al. Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. *Circulation.* 2009;120(11 Suppl):S1-S9.
40. Zafar M, Paz-Yepes M, Shimbo D, et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. *Eur Heart J.* 2010;31:1573-1582.
41. Frøbert O, Veer Mvt, Aarnoudse W, Simonsen U, Koolen JJ, Pijls NHJ. Acute myocardial infarction and underlying stenosis severity. *Catheter Cardiovasc Interv.* 2007;70(7):958-965.
42. Chan KH, Chawantpipat C, Gattorna T, et al. The relationship between coronary stenosis severity and compression type coronary artery movement in acute myocardial infarction. *Am Heart J.* 2010;159(4):584-592.
43. Manoharan G, Ntalianis A, Muller O, et al. Severity of coronary arterial stenoses responsible for acute coronary syndromes. *Am J Cardiol.* 2009;103(9):1183-1188.
44. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med.* 1987;316(22):1371-1375.
45. Fishbein MC, Siegel RJ. How big are coronary atherosclerotic plaques that rupture? *Circulation.* 1996;94(10):2662-2666.
46. Kaul P, Douglas PS. Atherosclerosis imaging: prognostically useful or merely more of what we know? *Circulation.* 2009;2(2):150-160.
47. Attili AK, Schuster A, Nagel E, Reiber JHC, van der Geest RJ. Quantification in cardiac MRI: advances in image acquisition and processing. *Int J Cardiovasc Imaging.* 2010;26 Suppl 1:27-40.
48. Yeager MP, Fillinger MP, Hettleman BD, Hartman GS. Perioperative beta-blockade and late cardiac outcomes: a complementary hypothesis. *J Cardiothorac Vasc Anesth.* 2005;19(2):237-241.
49. Galal W, Hoeks SE, Flu WJ, et al. Relation between preoperative and intraoperative new wall motion abnormalities in vascular surgery patients: a transesophageal echocardiographic study. *Anesthesiology.* 2010;112(3):557-566.
50. Poldermans D, Hoeks SE, Feringa HH. Pre-operative risk assessment and risk reduction before surgery. *J Am Coll Cardiol.* 2008;51(20):1913-1924.
51. McCann RL, Clements FM. Silent myocardial ischemia in patients undergoing peripheral vascular surgery: incidence and association with perioperative cardiac morbidity and mortality. *J Vasc Surg.* 1989;9(4):583-587.
52. Landesberg G, Mosseri M, Zahger D, et al. Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. *J Am Coll Cardiol.* 2001;37(7):1839-1845.
53. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW. Myocardial infarction after noncardiac surgery [published correction appears in *Anesthesiology.* 1999;90(2):644]. *Anesthesiology.* 1998;88(3):572-578.
54. Ausset S, Auroy Y, Lambert E, et al. Cardiac troponin I release after hip surgery correlates with poor long-term cardiac outcome. *Eur J Anaesthesiol.* 2008;25(2):158-164.
55. Zaugg M, Schaub MC, Foex P. Myocardial injury and its prevention in the perioperative setting. *Br J Anaesth.* 2004;93(1):21-33.
56. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. *N Engl J Med.* 1990;323(26):1781-1788.
57. Older P, Hall A, Hader R. Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly. *Chest.* 1999;116(2):355-362.
58. Howell SJ, Sear JW. Perioperative myocardial injury: individual and population implications. *Br J Anaesth.* 2004;93(1):3-8.
59. Parmar CD, Torella F. Prediction of major adverse cardiac events in vascular surgery: are cardiac risk scores of any practical value? *Vasc Endovasc Surg.* 2010;44(1):14-19.
60. Boersma E, Kertai MD, Schouten O, et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. *Am J Med.* 2005;118(10):1134-1141.

61. Ford MK, Beattie WS, Wijeyesundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. *Ann Intern Med.* 2010;152(1):26-35.
62. Glance LG. Selective preoperative cardiac screening improves five-year survival in patients undergoing major vascular surgery: a cost-effectiveness analysis. *J Cardiothorac Vasc Anesth.* 1999;13(3):265-271.
63. Roghi A, Palmieri B, Crivellaro W, Sara R, Puttini M, Faletta F. Preoperative assessment of cardiac risk in noncardiac major vascular surgery. *Am J Cardiol.* 1999;83(2):169-174.
64. Gilbert K, Larocque BJ, Patrick LT. Prospective evaluation of cardiac risk indices for patients undergoing noncardiac surgery. *Ann Intern Med.* 2000;133(5):356-359.
65. Paul SD, Eagle KA, Kuntz KM, Young JR, Hertzner NR. Concordance of preoperative clinical risk with angiographic severity of coronary artery disease in patients undergoing vascular surgery [published correction appears in *Circulation.* 1996;94(10):2668]. *Circulation.* 1996;94(7):1561-1566.
66. van Klei WA, Bryson GL, Yang H, Kalkman CJ, Wells GA, Beattie WS. The value of routine preoperative electrocardiography in predicting myocardial infarction after noncardiac surgery. *Ann Surg.* 2007;246(2):165-170.
67. L'Italien GJ, Paul SD, Hendel RC, et al. Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. *J Am Coll Cardiol.* 1996;27(4):779-786.
68. Chung F, Yuan H, Yin L, Vairavanathan S, Wong DT. Elimination of preoperative testing in ambulatory surgery. *Anesth Analg.* 2009;108(2):467-475.
69. Wijeyesundera DN, Beattie WS, Austin PC, Hux JE, Laupacis A. Non-invasive cardiac stress testing before elective major non-cardiac surgery: population based cohort study. *BMJ.* 2010;340:b5526.
70. Olson RP, Stone A, Lubarsky D. The prevalence and significance of low preoperative hemoglobin in ASA 1 or 2 outpatient surgery candidates. *Anesth Analg.* 2005;101(5):1337-1340.
71. Young LH, Wackers FJT, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA.* 2009;301(15):1547-1555.
72. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery [published correction appears in *J Am Coll Cardiol.* 2008;52(9):794-797. Note: Chaikof, Elliott (corrected to Chaikof, Elliott L)]. *J Am Coll Cardiol.* 2007;50(17):1707-1732.
73. Schein OD, Katz J, Bass EB, et al. The value of routine preoperative medical testing before cataract surgery. Study of medical testing for cataract surgery. *N Engl J Med.* 2000;342(3):168-175.
74. Kumar R, McKinney WP, Raj G, et al. Adverse cardiac events after surgery: assessing risk in a veteran population. *J Gen Intern Med.* 2001;16(8):507-518.
75. Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. *Eur J Endocrinol.* 2007;156(1):137-142.
76. Reilly DF, McNeely MJ, Doerner D, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. *Arch Intern Med.* 1999;159(18):2185-2192.
77. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). *Am J Cardiol.* 1989;64(10):651-654.
78. Girish M, Trayner E Jr, Dammann O, Pinto-Plata V, Celli B. Symptom-limited stair climbing as a predictor of postoperative cardiopulmonary complications after high-risk surgery. *Chest.* 2001;120(4):1147-1151.
79. Biccard BM. Relationship between the inability to climb two flights of stairs and outcome after major non-cardiac surgery: implications for the pre-operative assessment of functional capacity. *Anaesthesia.* 2005;60(6):588-593.
80. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. *Circulation.* 1998;97(1):26-33.
81. Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. *Circulation.* 1997;96(6):1882-1887.
82. Chassot PG, Delabays A, Spahn DR. Preoperative evaluation of patients with, or at risk of, coronary artery disease undergoing non-cardiac surgery. *Br J Anaesth.* 2002;89(5):747-759.
83. Posner KL, Van Norman GA, Chan V. Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. *Anesth Analg.* 1999;89(3):553-560.
84. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. *J Am Coll Cardiol.* 2000;35(5):1288-1294.
85. Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. *Anesthesiology.* 2008;109(4):588-595.
86. Iakovou I, Schmidt T, Bonizzi E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA.* 2005;293(17):2126-2130.
87. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol.* 2006;48(1):193-202.
88. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation.* 2007;115(6):813-818.
89. Rabbitts JA, Nuttall GA, Brown MJ, et al. Cardiac risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents. *Anesthesiology.* 2008;109(4):596-604.
90. Harjai KJ, Shenoy C, Orshaw P, Boura J. Dual antiplatelet therapy for more than 12 months after percutaneous coronary

- intervention: insights from the Guthrie PCI Registry. *Heart*. 2009;95(19):1579-1586.
91. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. *N Engl J Med*. 2010;362(15):1374-1382.
 92. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med*. 2010;362(18):1663-1674.
 93. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339(4):229-234.
 94. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a “Coronary Heart Disease Equivalent.” *Diabetes Care*. 2005;28(12):2901-2907.
Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects.
 95. Krolikowska M, Kataja M, Pöyhiä R, Drzewoski J, Hynynen M. Mortality in diabetic patients undergoing non-cardiac surgery: a 7-year follow-up study. *Acta Anaesthesiol Scand*. 2009;53(6):749-758.
 96. Subramaniam B, Pomposelli F, Talmor D, Park KW. Perioperative and long-term morbidity and mortality after above-knee and below-knee amputations in diabetics and nondiabetics. *Anesth Analg*. 2005;100(5):1241-1247.
 97. Hamdan AD, Saltzberg SS, Sheahan M, et al. Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. *Arch Surg*. 2002;137(4):417-421.
 98. American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care*. 2010;33(Suppl 1):S11-S61.
 99. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. *Anesthesiology*. 2008;108(4):559-567.
 100. Landesberg G, Einav S, Christopherson R, et al. Perioperative ischemia and cardiac complications in major vascular surgery: importance of the preoperative twelve-lead electrocardiogram. *J Vasc Surg*. 1997;26(4):570-578.
 101. Rodseth RN. B type natriuretic peptide—a diagnostic breakthrough in peri-operative cardiac risk assessment? *Anaesthesia*. 2009;64(2):165-178.
 102. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) [published correction appears in *Circulation*. 2006;113(22):e846]. *Circulation*. 2002;105(10):1257-1267.
 103. Hoeks SE, op Reimer WJMS, van Gestel YRBM, et al. Preoperative cardiac risk index predicts long-term mortality and health status. *Am J Med*. 2009;122(6):559-565.
 104. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA*. 2001;285(14):1865-1873.
 105. Kertai MD, Boersma E, Klein J, et al. Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model [published correction appears in *Arch Intern Med*. 2005;165(13):1540. Note: van Sambeek, Marc (added); Schouten, Olaf (added)]. *Arch Intern Med*. 2005;165(8):898-904.
 106. Ropper AH, Wechsler LR, Wilson LS. Carotid bruit and the risk of stroke in elective surgery. *N Engl J Med*. 1982;307(22):1388-1390.
 107. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. *Stroke*. 2004;35(10):2425-2427.
 108. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial [published correction appears in *Lancet*. 2004;364(9432):416]. *Lancet*. 2004;363(9420):1491-1502.
 109. Paciaroni M, Caso V, Acciarresi M, Baumgartner RW, Agnelli G. Management of asymptomatic carotid stenosis in patients undergoing general and vascular surgical procedures. *J Neurosurg Neurosurg Psychiatry*. 2005;76(10):1332-1336.
 110. Spence JD. Asymptomatic carotid stenosis: mainly a medical condition. *Vascular*. 2010;18(3):123-126; discussion 127-129.
 111. Ederle J, Featherstone RL, Brown MM, CAVATAS collaborators. Long-term outcome of endovascular treatment versus medical care for carotid artery stenosis in patients not suitable for surgery and randomised in the Carotid and Vertebral Artery Transluminal Angioplasty study (CAVATAS). *Cerebrovascular Dis*. 2009;28(1):1-7.
 112. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. *Stroke*. 2009;40(10):e573-583.
 113. Qureshi AI, Alexandrov AV, Tegeler CH, et al. Guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the multidisciplinary practice guidelines committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. *J Neuroimaging*. 2007;17(1):19-47.
 114. Kertai MD, Bountiokos M, Boersma E, et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. *Am J Med*. 2004;116(1):8-13.
 115. Christ M, Sharkova Y, Geldner G, Maisch B. Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. *Chest*. 2005;128(4):2944-2953.
 116. Ho MC, Beathe JC, Sharrock NE. Hypotensive epidural anesthesia in patients with aortic stenosis undergoing total hip replacement. *Reg Anesth Pain Med*. 2008;33(2):129-133.
 117. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in *Circulation*. 2007;116(15):e376-377]. *Circulation*. 2007;116(15):1736-1754.
 119. Cheng TO. Endocarditis prophylaxis in patients with mitral valve prolapse remains a controversial issue despite the new American Heart Association guidelines. *Int J Cardiol*. 2008;127(2):149-150.
 120. Gould FK, Elliott TSJ, Foweraker J, et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother*. 2006;57(6):1035-1042.

121. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). *Eur Heart J*. 2009;30(19):2369-2413.
122. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. *Circulation*. 2009;120(21):2053-2061.
123. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. *Mayo Clin Proc*. 2010;85(7):678-692.
124. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. *JAMA*. 2009;301(18):1909-1919.
125. Kies SJ, Pabelick CM, Hurley HA, White RD, Ackerman MJ. Anesthesia for patients with congenital long QT syndrome. *Anesthesiology*. 2005;102(1):204-210.
126. Torsades de pointes Web site. Drugs associated with prolongation of QT interval and risk of torsade de pointes. www.torsades.net.
127. Kjeldsen SE, Farsang C, Sleigh P, Mancia G; World Health Organization; International Society of Hypertension. 1999 WHO/ISH hypertension guidelines—highlights and esh update. *J Hypertens*. 2001;19(12):2285-2288.
128. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension*. 2006;47(5):846-853.
129. Howell SJ, Sear JW, Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. *Br J Anaesth*. 2004;92(4):570-583.
130. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006;113(9):1213-1225.
131. Mitchell GF, Conlin PR, Dunlap ME, et al. Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. *Hypertension*. 2008;51(1):105-111.
132. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. *Hypertension*. 2009;54(2):409-413.
133. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. *Am J Cardiol*. 2010;105(10):1433-1438.
134. Aznaouridis KA, Stamatelopoulos KS, Karatzis EN, Protogerou AD, Papamichael CM, Lekakis JP. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. *J Hum Hypertens*. 2007;21(8):654-663.
135. Gómez-Cerezo J, Rios Blanco JJ, Suarez Garcia I, et al. Noninvasive study of endothelial function in white coat hypertension. *Hypertension*. 2002;40(3):304-309.
136. Gustavsen PH, Høegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. *J Hum Hypertens*. 2003;17(12):811-817.
137. Karter Y, Curgunlu A, Altinisik S, et al. Target organ damage and changes in arterial compliance in white coat hypertension. Is white coat innocent? *Blood Press*. 2003;12(5-6):307-313.
138. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short- and long-term risk of cardiovascular events in white-coat hypertension. *J Hum Hypertens*. 2008;22(6):408-414.
139. Ben-Dov IZ, Kark JD, Mekler J, Shaked E, Bursztyn M. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. *J Hypertens*. 2008;26(4):699-705.
140. Beattie WS, Karkouti K, Wijeyesundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. *Anesthesiology*. 2009;110(3):574-581.
141. Surgenor SD, Kramer RS, Olmstead EM, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. *Anesth Analg*. 2009;108(6):1741-1746.
142. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. *Lancet*. 1996;348(9034):1055-1060.
143. Goodnough LT. Risks of blood transfusion. *Crit Care Med*. 2003;31(12 Suppl):S678-S686.
144. Naughton C, Feneck RO. The impact of age on 6-month survival in patients with cardiovascular risk factors undergoing elective non-cardiac surgery. *Int J Clin Pract*. 2007;61(5):768-776.
145. Welten GMJM, Schouten O, van Domburg RT, et al. The influence of aging on the prognostic value of the revised cardiac risk index for postoperative cardiac complications in vascular surgery patients. *Eur J Vasc Endovasc Surg*. 2007;34(6):632-638.
146. Bai J, Hashimoto J, Nakahara T, Suzuki T, Kubo A. Influence of ageing on perioperative cardiac risk in non-cardiac surgery. *Age Ageing*. 2007;36(1):68-72.
147. Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. *Ann Int Med*. 1997;127(4):313-328.
148. Martignani C, Diemberger I, Biffi M, et al. Troponin I rise after pacemaker implantation at the time of “universal definition of myocardial infarction.” *Am J Cardiol*. 2009;103(8):1061-1065.
149. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. *Circulation*. 2004;109(25 Suppl 1):IV31-46.
150. Luers C, Wachter R, Kleta S, et al. Natriuretic peptides in the detection of preclinical diastolic or systolic dysfunction. *Clin Res Cardiol*. 2010;99(4):217-226.
151. Mueller C. Cost-effectiveness of B-type natriuretic peptide testing. *Congest Heart Fail*. 2008;14(4 Suppl 1):35-37.
152. Rajagopalan S, Croal BL, Bachoo P, Hillis GS, Cuthbertson BH, Brittenden J. N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. *J Vasc Surg*. 2008;48(4):912-917; discussion 917.
153. Cuthbertson BH, Amiri AR, Croal BL, et al. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. *Br J Anaesth*. 2007;99(2):170-176.
154. Choi JH, Cho DK, Song YB, et al. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. *Heart*. 2010;96(1):56-62.
155. Fox AA, Shernan SK, Collard CD, et al. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2008;136(2):452-461.

156. Ridker PM, Cannon CP, Morrow D, Braunwald E. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med.* 2005;352:20-28.
157. Cappabianca G, Paparella D, Visicchio G, et al. Preoperative C-reactive protein predicts mid-term outcome after cardiac surgery. *Ann Thorac Surg.* 2006;82(6):2170-2178.
158. Perry TE, Muehlschlegel JD, Liu K-Y, et al. Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting. *Anesthesiology.* 2010;112(3):607-613.
159. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009;151(7):496-507.
160. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet.* 2009;373(9670):1175-1182.
161. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. *Am J Cardiol.* 2009;104(11):1603-1605.
162. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). *Am J Cardiol.* 2010;106(2):204-209.
163. Chan Y-H, Lau K-K, Yiu K-H, et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. *Eur Heart J.* 2008;29(22):2800-2807.
164. Frasure-Smith N, Lespérance F. Depression and cardiac risk: present status and future directions. *Heart.* 2010;96(3):173-176.
165. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. *Psychosom Med.* 2003;65(2):201-210.
166. Glassman AH, Bigger JT Jr, Gaffney M. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. *Arch Gen Psychiatry.* 2009;66(9):1022-1029.
167. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy [published correction appears in *Circulation.* 2003;108(25):3165]. *Circulation.* 2003;108(8):939-944.
168. Morel-Kopp MC, McLean L, Chen Q, et al. The association of depression with platelet activation: evidence for a treatment effect. *J Thromb Haemost.* 2009;7(4):573-581.
169. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. *Lancet.* 2003;362(9384):604-609.
170. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation.* 2010;121(4):512-518.
171. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. *Am J Epidemiol.* 2006;164(10):921-935.
172. Liu K-Y, Muehlschlegel JD, Perry TE, et al. Common genetic variants on chromosome 9p21 predict perioperative myocardial injury after coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg.* 2010;139(2):483-488.
173. Böttiger C, Koch W, Lahn C, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. *Am Heart J.* 2003;146(5):855-861.
174. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. *J Thromb Haemost.* 2006;4(4):912-914.
175. Rinder CS, Mathew JP, Rinder HM, et al. Platelet PIA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. *Anesthesiology.* 2002;97(5):1118-1122.
176. Ziegeler S, Tsusaki BE, Collard CD. Influence of genotype on perioperative risk and outcome. *Anesthesiology.* 2003;99(1):212-219.
177. Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten S-E. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. *Anesth. Analg.* 2003;97(4):944-949.
178. Podgoreanu MV, White WD, Morris RW, et al. Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. *Circulation.* 2006;114(1 Suppl):I275-281.
179. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. *JAMA.* 2005;294(12):1526-1533.
180. Zaugg M, Schaub MC. Genetic modulation of adrenergic activity in the heart and vasculature: implications for perioperative medicine. *Anesthesiology.* 2005;102(2):429-446.
181. Zaugg M, Bestmann L, Wacker J, et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. *Anesthesiology.* 2007;107(1):33-44.
182. Schouten O, van Kuijk J-P, Flu W-J, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). *Am J Cardiol.* 2009;103(7):897-901.
183. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007;356(15):1503-1516.
184. Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? *J Am Coll Cardiol.* 2006;48(5):964-969.
185. Filipovic M, Jeger RV, Girard T, et al. Predictors of long-term mortality and cardiac events in patients with known or suspected coronary artery disease who survive major non-cardiac surgery. *Anaesthesia.* 2005;60(1):5-11.
186. Flu W-J, van Kuijk J-P, Hoeks SE, et al. Intima media thickness of the common carotid artery in vascular surgery patients: a predictor of postoperative cardiovascular events. *Am Heart J.* 2009;158(2):202-208.
187. Garcia MJ. Cardiac CT for CAD. Do we still need angiography? *J Cardiovasc Surg.* 2009;50(1):7-17.
188. Raggi P. Cardiac CT in asymptomatic patients at risk. *Cardiol Clin.* 2009;27(4):605-610.

189. Ishida M, Kato S, Sakuma H. Cardiac MRI in ischemic heart disease. *Circ J*. 2009;73(9):1577-1588.
190. Liu LL, Dzankic S, Leung JM. Preoperative electrocardiogram abnormalities do not predict postoperative cardiac complications in geriatric surgical patients. *J Am Geriatr Soc*. 2002;50(7):1186-1191.
191. Thanh NX, Rashid S, Jonsson E. Routine preoperative electrocardiogram and chest x-ray prior to elective surgery in Alberta, Canada. *Can J Anaesth*. 2010;57(2):127-133.
192. Correll DJ, Hepner DL, Chang C, Tsen L, Hevelone ND, Bader AM. Preoperative electrocardiograms: patient factors predictive of abnormalities. *Anesthesiology*. 2009;110(6):1217-1222.
193. De Hert SG. Preoperative electrocardiograms: obsolete or still useful? *Anesthesiology*. 2009;110(6):1205-1206.
194. Quiñones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of left ventricular dysfunction. *J Am Coll Cardiol*. 2000;35(5):1237-1244.
195. Hawkins NM, Wang D, McMurray JJV, et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. *Heart*. 2007;93(1):59-64.
196. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. *Am J Cardiol*. 1999;83(5):660-666.
197. Mahajan N, Polavaram L, Vankayala H, et al. Diagnostic accuracy of myocardial perfusion imaging and stress echocardiography for the diagnosis of left main and triple vessel coronary artery disease: a comparative meta-analysis. *Heart*. 2010;96(12):956-966.
198. Beattie WS, Abdelnaem E, Wijeyesundera DN, Buckley DN. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. *Anesth Analg*. 2006;102(1):8-16.
199. Geleijnse ML, Krenning BJ, van Dalen BM, et al. Factors affecting sensitivity and specificity of diagnostic testing: dobutamine stress echocardiography. *J Am Soc Echocardiogr*. 2009;22(11):1199-1208.
200. Chan SY, Mancini GBJ, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. *J Am Coll Cardiol*. 2003;42(6):1037-1043.
201. Muiesan ML, Salvetti M, Paini A, et al. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. *J Hypertens*. 2008;26(8):1612-1618.
202. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. *Am J Cardiol*. 2006;98(11):1424-1428.
203. Wright DE, Hunt DP. Perioperative surveillance for adverse myocardial events. *South Med J*. 2008;101(1):52-58.
204. Rinfret S, Goldman L, Polanczyk CA, Cook EF, Lee TH. Value of immediate postoperative electrocardiogram to update risk stratification after major noncardiac surgery. *Am J Cardiol*. 2004;94(8):1017-1022.
205. Böttiger BW, Motsch J, Teschendorf P, et al. Postoperative 12-lead ECG predicts peri-operative myocardial ischemia associated with myocardial cell damage. *Anaesthesia*. 2004;59(11):1083-1090.
206. Chong CP, Lam QT, Ryan JE, Sinnappu RN, Lim WK. Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients. *Age Ageing*. 2009;38(2):168-174.
207. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. *J Am Coll Cardiol*. 2003;42(9):1547-1554.
208. Wackers FJT, Chyun DA, Young LH, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. *Diabetes Care*. 2007;30(11):2892-2898.
209. Biccard BM, Rodseth RN. A meta-analysis of the prospective randomised trials of coronary revascularisation before noncardiac vascular surgery with attention to the type of coronary revascularisation performed. *Anaesthesia*. 2009;64(10):1105-1113.
210. de Virgilio C, Wall DB, Ephraim L, et al. An abnormal dipyridamole thallium/sestamibi fails to predict long-term cardiac events in vascular surgery patients. *Ann Vasc Surg*. 2001;15(2):267-271.
211. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. *Anesthesiology*. 1979;50(4):285-292.
212. Casadei B, Abuzeid H. Is there a strong rationale for deferring elective surgery in patients with poorly controlled hypertension? *J Hypertens*. 2005;23(1):19-22.
213. De Gaudio AR, Chelazzi C, Villa G, Cavaliere F. Acute severe arterial hypertension: therapeutic options. *Curr Drug Targets*. 2009;10(8):788-798.
214. Fleisher LA. Preoperative evaluation of the patient with hypertension. *JAMA*. 2002;287(16):2043-2046.
215. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. *J Am Coll Cardiol*. 2002;40(3):505-510.
216. Warner MA, Offord KP, Warner ME, Lennon RL, Conover MA, Jansson-Schumacher U. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. *Mayo Clin Proc*. 1989;64(6):609-616.
217. Yamashita S, Yamaguchi H, Sakaguchi M, et al. Effect of smoking on intraoperative sputum and postoperative pulmonary complication in minor surgical patients. *Respir Med*. 2004;98(8):760-766.
- 217A. Møller AM, Pedersen T, Villebro N, Munksgaard A. Effect of smoking on early complications after elective orthopaedic surgery. *J Bone Joint Surg Br*. 2003;85(2):178-181.
218. Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. *J Thorac Oncol*. 2009;4(4):499-504.
219. Devereaux PJ, Beattie WS, Choi PTL, et al. How strong is the evidence for the use of perioperative beta blockers in noncardiac surgery? Systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2005;331(7512):313-321.
220. Group PS, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): a randomised controlled trial. *Lancet*. 2008;371(9627):1839-1847.
221. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, et al. 2009 ACCF/AHA focused update on perioperative beta blockade. *J Am Coll Cardiol*. 2009;54(22):2102-2128.

222. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. *Eur Heart J*. 2007;28(24):3012-3019.
223. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine [published correction appears in *Circulation*. 2008;117(9):e180]. *Circulation*. 2007;116(7):e148-304.
224. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*. 2005;366(9489):907-913.
225. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group [published correction appears in *N Engl J Med* 1997;336(14):1039]. *N Engl J Med*. 1996;335(23):1713-1720.
226. Sear JW, Howell SJ, Sear YM, Yeates D, Goldacre M, Foex P. Intercurrent drug therapy and perioperative cardiovascular mortality in elective and urgent/emergency surgical patients. *Br J Anaesth*. 2001;86(4):506-512.
227. Johansen JW, Schneider G, Windsor AM, Sebel PS. Esmolol potentiates reduction of minimum alveolar isoflurane concentration by alfentanil. *Anesth Analg*. 1998;87(3):671-676.
228. Oda Y, Nishikawa K, Hase I, Asada A. The short-acting beta1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. *Anesth Analg*. 2005;100(3):733-737.
229. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. [Summary for patients in *Ann Intern Med*. 2002;137(9):I31]. *Ann Intern Med*. 2002;137(9):715-725.
230. van Gestel YRBM, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. *Am J Respir Crit Care Med*. 2008;178(7):695-700.
231. Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. *Arch Intern Med*. 2010;170(10):880-887.
232. Auerbach AD, Goldman L. beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. *JAMA*. 2002;287(11):1435-1444.
233. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009;120(21):e169-276.
234. *Hypertension: Management in Adults in Primary Care: Pharmacological Update*. The National Collaborating Centre for Chronic Conditions. London, UK: Royal College of Physicians; 2006.
235. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina [published correction appears in *Circulation*. 2007;116(23):e558 Note: Pasternak, Richard C (removed)]. *Circulation*. 2007;116(23):2762-2772.
236. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005;366(9497):1622-1632.
237. Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. *Ann Intern Med*. 2007;147(1):10-18.
238. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. *Circulation*. 2005;112(12):e154-235.
239. Klapholz M. Beta-blocker use for the stages of heart failure. *Mayo Clin Proc*. 2009;84(8):718-729.
240. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation*. 2009;119(14):1977-2016.
241. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004;292(18):2227-2236.
242. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial [reprint in *Curr Hypertens Rep*. 2006;8(3):229-231]. *Lancet*. 2005;366(9489):895-906.
243. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis [published correction appears in *Lancet*. 2007;369(9572):1518]. *Lancet*. 2007;369(9557):201-207.
244. Frishman WH, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. *Vasc Health Risk Manag*. 2008;4(6):1387-1400.
245. Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. *Clin Ther*. 2009;31(3):447-462.
246. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). *Ann Surg*. 2009;249(6):921-926.

247. Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. *Clin Pharmacol Ther.* 2009;85(3):269-272.
248. Giles JW, Sear JW, Foëx P. Effect of chronic beta-blockade on peri-operative outcome in patients undergoing non-cardiac surgery: an analysis of observational and case control studies. *Anaesthesia.* 2004;59(6):574-583.
249. Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. *Am Heart J.* 2001;141(1):148-153.
250. Teichert M, de Smet PAGM, Hofman A, Witteman JCM, Stricker BHC. Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly. *Drug Saf.* 2007;30(6):541-549.
251. Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). *Circulation.* 1998;97:1453-1460.
252. Lemiengre M, van Driel M, Chevalier P, De Meyere M, Christiaens T. New analyses of Heart Protection Study. *Lancet.* 2004;363(9423):1827-1828; author reply 1828.
253. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. *Am J Cardiol.* 2001;88:1306-1307.
254. Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. *Circ Res.* 2003;93:98-103.
255. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol.* 2007;49(12):1272-1278.
256. Liu P-Y, Liu Y-W, Lin L-J, Chen J-H, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. *Circulation.* 2009;119:131-138.
257. Rawlings R, Nohria A, Liu P-Y, et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. *Am J Cardiol.* 2009;103:437-441.
258. Durazzo AES, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg.* 2004;39(5):967-975; discussion 975-976.
259. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. *N Engl J Med.* 2009;361:980-989.
260. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. *Anesthesiology.* 2006;105:1260-1272.
261. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. *Anesth Analg.* 2007;104:1326-1333.
262. Sever PS, Poulter NR, Dahlöf B, Wedel H, Anglo-Scandinavian Cardiac Outcomes Trial I. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). *Am J Cardiol.* 2005;96(5A):39F-44F.
263. Reich DL, Hossain S, Krol M, et al. Predictors of hypotension after induction of general anesthesia. *Anesth Analg.* 2005;101(3):622-628.
264. Colson P, Ryckwaert F, Coriat P. Renin angiotensin system antagonists and anesthesia. *Anesth Analg.* 1999;89(5):1143-1155.
265. Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. *Anesth Analg.* 2005;100(3):636-644.
266. Bertrand M, Godet G, Meerschaert K, Brun L, Salcedo E, Coriat P. Should the angiotensin II antagonists be discontinued before surgery? *Anesth Analg.* 2001;92(1):26-30.
267. Shahzamani M, Yousefi Z, Frootaghe AN, et al. The effect of angiotensin-converting enzyme inhibitor on hemodynamic instability in patients undergoing cardiopulmonary bypass: results of a dose-comparison study. *J Cardiovasc Pharmacol Ther.* 2009;14(3):185-191.
268. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA.* 2004;292(18):2217-2225.
269. Wijeyundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. *Anesth Analg.* 2003;97(3):634-641.
270. Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology (ESC); Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). [Reprint in *Eur J Anaesthesiol.* 2010;27(2):92-137]. *Eur Heart J.* 2009;30(22):2769-2812.
271. Kertai MD, Westerhout CM, Varga KS, Acsady G, Gal J. Dihydropyridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery. *Br J Anaesth.* 2008;101(4):458-465.
272. Feringa HHH, Bax JJ, Schouten O, Poldermans D. Protecting the heart with cardiac medication in patients with left ventricular dysfunction undergoing major noncardiac vascular surgery. *Semin Cardiothorac Vasc Anesth.* 2006;10(1):25-31.
273. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. *Arch Intern Med.* 2009;169(9):832-842.
274. Nishina K, Mikawa K, Uesugi T, et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. *Anesthesiology.* 2002;96(2):323-329.
275. Wijeyundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med.* 2003;114(9):742-752.
276. Dodds TM, Stone JG, Coromilas J, Weinberger M, Levy DG. Prophylactic nitroglycerin infusion during noncardiac surgery does not reduce perioperative ischemia. *Anesth Analg.* 1993;76(4):705-713.
277. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):299S-339S.
278. Taylor DW, Barnett HJM, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid

- endarterectomy: a randomised controlled trial. *Lancet*. 1999;353(9171):2179-2184.
279. Payne DA, Jones CI, Hayes PD, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. *Circulation*. 2004;109(12):1476-1481.
 280. Anekstein Y, Tamir E, Halperin N, Mirovsky Y. Aspirin therapy and bleeding during proximal femoral fracture surgery. *Clin Orthop Relat Res*. 2004;418:205-208.
 281. O'Riordan JM, Margey RJ, Blake G, O'Connell PR. Antiplatelet agents in the perioperative period. *Arch Surg*. 2009;144(1):69-76.
 282. Biondi-Zoccai GGL, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. *Eur Heart J*. 2006;27(22):2667-2674.
 283. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. *Circulation*. 2004;110(16):2361-2367.
 284. Berger JS, Brown DL, Burke GL, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. *Circulation*. 2009;120(2):78-87.
 285. Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. *Br J Anaesth*. 2010;104(3):305-312.
 286. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2008;118(15):e523-661.
 287. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):457S-482S.
 288. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. *Circulation*. 2004;110(12):1658-1663.
 289. Shlebak A, Malik I. Managing heparin anticoagulation in patients with prosthetic cardiac valves: balancing the risk. *Heart*. 2009;95(20):1643-1645.
 290. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J*. 2007;28(2):230-268.
 291. Luckie M, Khattar RS, Fraser D. Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. *Heart*. 2009;95(16):1303-1308.
 292. Vicenzi MN, Meislitz T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery—a prospective outcome study. *Br J Anaesth*. 2006;96(6):686-693.
 293. Newsome LT, Weller RS, Gerancher JC, Kutcher MA, Royster RL. Coronary artery stents: II. Perioperative considerations and management. *Anesth Analg*. 2008;107(2):570-590.
 294. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. *Br J Anaesth*. 2010;104(3):285-291.
 295. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2010;4:CD002967.
 296. Vitale C, Mercurio G, Cornoldi A, Fini M, Volterrani M, Rosano GMC. Metformin improves endothelial function in patients with metabolic syndrome. *J Intern Med*. 2005;258(3):250-256.
 297. Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intima-media thickness and nitrooxidation in metabolic syndrome: the mefisto study. *Clin Exp Pharmacol Physiol*. 2008;35(8):895-903.
 298. Estrada CA, Young JA, Nifong LW, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. *Ann Thorac Surg*. 2003;75(5):1392-1399.
 299. Talbot TR. Diabetes mellitus and cardiothoracic surgical site infections. *Am J Infect Control*. 2005;33(6):353-359.
 300. Shankar A, Klein R, Klein BEK, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. *Am J Epidemiol*. 2007;166(4):393-402.
 301. Kao LS, Meeks D, Moyer VA, Lally KP. Peri-operative glycaemic control regimens for preventing surgical site infections in adults. *Cochrane Database Syst Rev*. 2009(3):CD006806.
 302. Akhtar S, Barash PG, Inzucchi SE. Scientific principles and clinical implications of perioperative glucose regulation and control. *Anesth Analg*. 2010;110(2):478-497.
 303. Duncan AE, Abd-Elseyed A, Maheshwari A, Xu M, Soltesz E, Koch CG. Role of intraoperative and postoperative blood glucose concentrations in predicting outcomes after cardiac surgery. *Anesthesiology*. 2010;112(4):860-871.
 304. Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workshop. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Am J Surg*. 2005;189(4):395-404.
 305. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. *Diabet Med*. 2008;25(3):320-325.
 306. de Roos B, Mavrommatis Y, Brouwer IA. Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. *Br J Pharmacol*. 2009;158(2):413-428.
 307. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). *Reg Anesth Pain Med*. 2010;35(1):64-101.
 308. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Engl J Med*. 1977;297(16):845-850.
 309. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. *J Gen Intern Med*. 1986;1(4):211-219.
 310. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. *Anesthesiology*. 2004;101(2):284-293.